54 citations
,
August 1981 in “British Journal of Dermatology” Alopecia areata is linked to reduced T cell function and auto-immunity.
3 citations
,
August 2022 in “International Journal of Molecular Sciences” TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.
3 citations
,
April 2023 in “Cytotechnology” 2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
Loss of Dnmt3a and Dnmt3b increases aggressive skin tumors by affecting PPAR-γ.
April 2023 in “Journal of Investigative Dermatology” Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.
2 citations
,
January 2026 in “Frontiers in Endocrinology” Next-generation Treg therapies could help achieve lasting immune tolerance in type 1 diabetes.
November 2022 in “Journal of Investigative Dermatology” ILC1-like cells can cause alopecia areata by affecting hair follicles.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
April 2021 in “Journal of Investigative Dermatology” 3 citations
,
December 2023 in “Aging” hsa_circ_0002980 can help stop liver cancer cells from growing and spreading.
10 citations
,
July 2021 in “Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin” LRIG1 is linked to better survival in Merkel cell carcinoma.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
1 citations
,
July 2025 in “Cancer Medicine” Colorectal cancer cells can adapt without losing their traits or drug sensitivity.
April 2023 in “Journal of Investigative Dermatology” Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
January 2014 in “Journal of Jilin University” Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.
39 citations
,
May 2014 in “Frontiers in Pharmacology” Special immune cells called Tregs can help prevent lung scarring by blocking a specific growth factor.
60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
March 2024 in “International Journal of Cosmetic Science” Dandruff is linked to increased T cells and weakened immune protection in hair follicles.
September 2024 in “Journal of the Pakistan Medical Association” A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.
April 2023 in “Cancer research” KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
28 citations
,
May 2012 in “Experimental Dermatology” 1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
April 2010 in “Cancer Research” Stat3 activation increases hair follicle progenitors but reduces bulge region stem cells.
4 citations
,
July 2008 in “British journal of dermatology/British journal of dermatology, Supplement” Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.